Trial · NCT03759184
Results by group30
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 30
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Treatment-emergent Adverse Events (AEs) Related to Recombinant Human Interleukin-15 (rhIL-15) | Arm 1 - Dose Escalation - Dose Level 1 | 0 | adverse events | ||
| Number of Treatment-emergent Adverse Events (AEs) Related to Obinutuzumab | Arm 1 - Dose Escalation - Dose Level 1 | 0 | adverse events | ||
| Number of Participants With a Grades 3-5 Dose-limiting Toxicity (DLT) of Continuous Intravenous (CIV) Recombinant Human Interleukin-15 (rhIL-15) Treatment | Arm 1 - Dose Escalation - Dose Level 1 | Grade 3 Possibly Related | 0 | Participants | |
| Number of Participants With a Grades 3-5 Dose-limiting Toxicity (DLT) of Continuous Intravenous (CIV) Recombinant Human Interleukin-15 (rhIL-15) Treatment | Arm 1 - Dose Escalation - Dose Level 1 | Grade 3 Probably Related | 0 | Participants | |
| Number of Participants With a Grades 3-5 Dose-limiting Toxicity (DLT) of Continuous Intravenous (CIV) Recombinant Human Interleukin-15 (rhIL-15) Treatment | Arm 1 - Dose Escalation - Dose Level 1 | Grade 3 Definitely Related | 0 | Participants | |
| Number of Participants With a Grades 3-5 Dose-limiting Toxicity (DLT) of Continuous Intravenous (CIV) Recombinant Human Interleukin-15 (rhIL-15) Treatment | Arm 1 - Dose Escalation - Dose Level 1 | Grade 4 Possibly Related | 0 | Participants | |
| Number of Participants With a Grades 3-5 Dose-limiting Toxicity (DLT) of Continuous Intravenous (CIV) Recombinant Human Interleukin-15 (rhIL-15) Treatment | Arm 1 - Dose Escalation - Dose Level 1 | Grade 4 Probably Related | 0 | Participants | |
| Number of Participants With a Grades 3-5 Dose-limiting Toxicity (DLT) of Continuous Intravenous (CIV) Recombinant Human Interleukin-15 (rhIL-15) Treatment | Arm 1 - Dose Escalation - Dose Level 1 | Grade 4 Definitely Related | 0 | Participants | |
| Number of Participants With a Grades 3-5 Dose-limiting Toxicity (DLT) of Continuous Intravenous (CIV) Recombinant Human Interleukin-15 (rhIL-15) Treatment | Arm 1 - Dose Escalation - Dose Level 1 | Grade 5 Possibly Related | 0 | Participants | |
| Number of Participants With a Grades 3-5 Dose-limiting Toxicity (DLT) of Continuous Intravenous (CIV) Recombinant Human Interleukin-15 (rhIL-15) Treatment | Arm 1 - Dose Escalation - Dose Level 1 | Grade 5 Probably Related | 0 | Participants | |
| Number of Participants With a Grades 3-5 Dose-limiting Toxicity (DLT) of Continuous Intravenous (CIV) Recombinant Human Interleukin-15 (rhIL-15) Treatment | Arm 1 - Dose Escalation - Dose Level 1 | Grade 5 Definitely Related | 0 | Participants | |
| Number of Participants With a Grade 3-5 Dose-limiting Toxicity (DLT) With Intravenous (IV) Obinutuzumab Treatment | Arm 1 - Dose Escalation - Dose Level 1 | Grade 3 Possibly Related | 0 | Participants | |
| Number of Participants With a Grade 3-5 Dose-limiting Toxicity (DLT) With Intravenous (IV) Obinutuzumab Treatment | Arm 1 - Dose Escalation - Dose Level 1 | Grade 3 Probably Related | 0 | Participants | |
| Number of Participants With a Grade 3-5 Dose-limiting Toxicity (DLT) With Intravenous (IV) Obinutuzumab Treatment | Arm 1 - Dose Escalation - Dose Level 1 | Grade 3 Definitely Related | 0 | Participants | |
| Number of Participants With a Grade 3-5 Dose-limiting Toxicity (DLT) With Intravenous (IV) Obinutuzumab Treatment | Arm 1 - Dose Escalation - Dose Level 1 | Grade 4 Possibly Related | 0 | Participants | |
| Number of Participants With a Grade 3-5 Dose-limiting Toxicity (DLT) With Intravenous (IV) Obinutuzumab Treatment | Arm 1 - Dose Escalation - Dose Level 1 | Grade 4 Probably Related | 0 | Participants | |
| Number of Participants With a Grade 3-5 Dose-limiting Toxicity (DLT) With Intravenous (IV) Obinutuzumab Treatment | Arm 1 - Dose Escalation - Dose Level 1 | Grade 4 Definitely Related | 0 | Participants | |
| Number of Participants With a Grade 3-5 Dose-limiting Toxicity (DLT) With Intravenous (IV) Obinutuzumab Treatment | Arm 1 - Dose Escalation - Dose Level 1 | Grade 5 Possibly Related | 0 | Participants | |
| Number of Participants With a Grade 3-5 Dose-limiting Toxicity (DLT) With Intravenous (IV) Obinutuzumab Treatment | Arm 1 - Dose Escalation - Dose Level 1 | Grade 5 Probably Related | 0 | Participants | |
| Number of Participants With a Grade 3-5 Dose-limiting Toxicity (DLT) With Intravenous (IV) Obinutuzumab Treatment | Arm 1 - Dose Escalation - Dose Level 1 | Grade 5 Definitely Related | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03759184/results